Grufity logoGrufity logo

Guardant Health, Inc. Stock Research

GH

28.26USD+1.48(+5.53%)Market Closed

Market Summary

USD28.26+1.48
Market Closed
5.53%

GH Alerts

GH Stock Price

GH RSI Chart

GH Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-4.43

Price/Sales (Trailing)

6.45

EV/EBITDA

-4.49

Price/Free Cashflow

-7.5

GH Price/Sales (Trailing)

GH Profitability

EBT Margin

-145.36%

Return on Equity

-1.1K%

Return on Assets

-40.66%

Free Cashflow Yield

-13.34%

GH Fundamentals

GH Revenue

Revenue (TTM)

449.5M

Revenue Y/Y

17.37%

Revenue Q/Q

8.08%

GH Earnings

Earnings (TTM)

-654.6M

Earnings Y/Y

-93.52%

Earnings Q/Q

13.62%

Price Action

52 Week Range

24.2077.72
(Low)(High)

Last 7 days

-7.3%

Last 30 days

-3.8%

Last 90 days

-35.1%

Trailing 12 Months

-45.1%

GH Financial Health

Current Ratio

6.17

GH Investor Care

Shares Dilution (1Y)

0.84%

Diluted EPS (TTM)

-6.41

Peers (Alternatives to Guardant Health)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
70.6B
60.2B
-4.86% -6.89%
12.5
1.17
2.52% -18.88%
19.6B
14.9B
-11.65% -18.57%
15.35
1.32
-7.72% -46.20%
15.5B
9.9B
-9.17% -4.78%
16.43
1.57
-8.39% -52.58%
MID-CAP
8.8B
13.4B
-20.72% -21.03%
13
0.66
5.99% -31.87%
5.3B
4.3B
-15.50% -2.92%
19.39
1.21
8.31% -34.26%
5.2B
2.3B
3.17% 35.63%
86.23
2.28
2.85% -58.05%
5.0B
3.0B
-3.25% 4.25%
22.21
1.65
15.15% 15.43%
3.6B
5.2B
-10.88% -15.90%
8.03
0.68
31.60% 35.63%
2.9B
449.5M
-3.81% -45.08%
-4.43
6.45
20.31% -70.12%
2.5B
2.2B
-17.56% -48.92%
20.74
1.11
0.41% -43.27%
SMALL-CAP
1.3B
1.4B
12.22% 10.36%
120.12
0.89
8.74% -56.93%
524.3M
2.8B
-3.12% -59.80%
-2.2
0.19
2.43% -140.13%
58.0M
98.8M
-21.26% -67.11%
-2.18
0.59
-14.50% -605.55%
38.5M
45.4M
-7.42% -70.30%
-0.96
0.85
-5.93% -72.41%
33.4M
26.0M
7.45% -10.59%
-16.54
1.28
9.09% -588.38%

Financials for Guardant Health

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue4.4%449,538,000430,755,000408,130,000391,087,000373,653,000
  S&GA Expenses7.9%299,828,000278,004,000247,862,000221,975,000191,881,000
  R&D Expenses9.9%373,807,000340,250,000311,201,000289,470,000263,221,000
EBITDA-11.4%-614,910,000-551,958,000-501,772,000-374,508,000-
EBITDA Margin-6.8%-1.37-1.28-1.23-0.96-
Earnings Before Taxes-11.4%-653,449,000-586,417,000-531,968,000-400,474,000-384,470,000
EBT Margin-6.8%-1.45-1.36-1.30-1.02-
Interest Expenses0.0%2,577,0002,576,0002,576,0002,575,0002,577,000
Net Income-11.5%-654,588,000-586,965,000-532,497,000-400,640,000-384,770,000
Net Income Margin-6.9%-1.46-1.36-1.30-1.02-
Free Cahsflow0.2%-386,924,000-387,787,000-363,195,000-309,494,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-5.4%1,6101,7021,8542,1302,204
  Current Assets5.4%1,1921,1311,0371,1131,114
    Cash Equivalents-10.5%142158215574492
  Inventory-18.2%52.0063.0060.0037.0031.00
  Net PPE-0.1%168168163151124
  Goodwill0%3.003.003.003.003.00
Liabilities1.0%1,5501,5351,5351,5971,559
  Current Liabilities10.3%193175168229195
Shareholder's Equity-63.9%60.00167319533645
  Retained Earnings-9.2%-1,662-1,522-1,360-1,131-1,007
  Additional Paid-In Capital1.5%1,7421,7161,7041,6821,658
Accumulated Depreciation13.1%70.0061.0055.00--
Shares Outstanding0.2%103102102102102
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-4.7%-309-295-270-221-209
  Share Based Compensation-3.2%95.0098.00112121151
Cashflow From Investing179.9%150-187-276-76.22-63.15
Cashflow From Financing-0.8%-189-187-1733.00-66.82

Risks for GH

What is the probability of a big loss on GH?

95.3%


Probability that Guardant Health stock will be more than 20% underwater in next one year

82.5%


Probability that Guardant Health stock will be more than 30% underwater in next one year.

54.5%


Probability that Guardant Health stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Guardant Health was unfortunately bought at previous high price.

Drawdowns

Returns for GH

Cumulative Returns on GH

-27.7%


3-Year Cumulative Returns

Which funds bought or sold GH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-0.05
-290,384
296,616
-%
2023-03-06
Rockefeller Capital Management L.P.
added
20.2
-693,000
1,071,000
-%
2023-02-28
Voya Investment Management LLC
added
4.35
-33,437,000
37,298,000
0.05%
2023-02-24
NATIXIS
sold off
-100
-1,354,000
-
-%
2023-02-24
SRS Capital Advisors, Inc.
unchanged
-
-2,280
2,720
-%
2023-02-21
Adalta Capital Management LLC
reduced
-18.2
-3,234,000
2,278,000
1.61%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
reduced
-41.21
-14,179
5,821
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-100
-116,000
-
-%
2023-02-17
TRUIST FINANCIAL CORP
reduced
-11.23
-454,140
368,860
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
added
2.65
-5,413
11,587
-%

1–10 of 38

Latest Funds Activity

Are funds buying GH calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own GH
No. of Funds

Guardant Health News

Nasdaq

Health Care Sector Update for 03/16/2023: GH, MGNX, ESPR.

Nasdaq,
2 days ago

InvestorsObserver

Nasdaq

Schedule 13G FIlings of Guardant Health

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 10, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2023
viking global investors lp
4.0%
4,107,644
SC 13G/A
Feb 13, 2023
capital international investors
7.7%
7,879,355
SC 13G
Feb 13, 2023
capital research global investors
2.0%
2,001,782
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.83%
9,040,240
SC 13G/A
Feb 03, 2023
blackrock inc.
5.4%
5,495,293
SC 13G
Mar 09, 2022
blackrock inc.
4.9%
4,961,865
SC 13G/A
Feb 11, 2022
capital research global investors
7.8%
7,927,702
SC 13G
Feb 10, 2022
fmr llc
-
0
SC 13G/A

GH Fair Value

Guardant Health fair value in different scenarios

The table shows the Fair Value estimates for Guardant Health for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

0.48

-98.30%

2.81

-90.06%

7.07

-74.98%

11.13

-60.62%
Current Inflation

0.29

-98.97%

0.34

-98.80%

2.36

-91.65%

6.02

-78.70%

9.49

-66.42%
Very High Inflation

-

-

0.17

-99.40%

1.84

-93.49%

4.79

-83.05%

7.59

-73.14%

Historical Guardant Health Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Guardant Health

View All Filings
Date Filed Form Type Document
Mar 16, 2023
4
Insider Trading
Mar 16, 2023
4
Insider Trading
Mar 16, 2023
4
Insider Trading
Mar 15, 2023
4
Insider Trading
Mar 13, 2023
8-K
Current Report
Mar 10, 2023
SC 13G/A
Major Ownership Report
Mar 07, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading

Latest Insider Trading transactions for GH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-14
Talasaz AmirAli
bought
112,188
26.3972
4,250
co-chief executive officer
2023-03-14
Talasaz AmirAli
bought
224,376
26.3972
8,500
co-chief executive officer
2023-03-13
Talasaz AmirAli
bought
513,107
25.6554
20,000
co-chief executive officer
2023-03-13
Talasaz AmirAli
bought
1,026,220
25.6554
40,000
co-chief executive officer
2023-03-04
Joyce Meghan V.
acquired
-
-
66.00
-
2023-03-03
Kalia Kumud
sold
-207,466
31.9179
-6,500
chief information officer
2023-03-01
Saia John G.
acquired
-
-
263
chief legal officer
2023-03-01
Kalia Kumud
sold (taxes)
-7,222
29.36
-246
chief information officer

1–10 of 50

Helmy Eltoukhy
1370
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

GH Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:   
Precision oncology testing$ 392,049$ 304,312$ 236,324
Development services and other57,48969,34150,406
Total revenue449,538373,653286,730
Costs and operating expenses:   
Cost of precision oncology testing148,199110,39674,769
Cost of development services and other8,12612,51617,766
Research and development expense373,807263,221149,862
Sales and marketing expense299,828191,881106,513
General and administrative expense163,956206,640192,770
Total costs and operating expenses993,916784,654541,680
Loss from operations(544,378)(411,001)(254,950)
Interest income6,0693,93010,171
Interest expense(2,577)(2,577)(4,766)
Other income (expense), net(12,778)25,1783,641
Fair value adjustments of noncontrolling interest liability(99,785)00
Loss before provision for income taxes(653,449)(384,470)(245,904)
Provision for income taxes1,139300379
Net loss(654,588)(384,770)(246,283)
Adjustment of redeemable noncontrolling interest0(20,900)(7,500)
Net loss attributable to Guardant Health, Inc. common stockholders - basic(654,588)(405,670)(253,783)
Net loss attributable to Guardant Health, Inc. common stockholders - diluted$ (654,588)$ (405,670)$ (253,783)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)$ (6.41)$ (4.00)$ (2.60)
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)$ (6.41)$ (4.00)$ (2.60)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)102,178101,31497,504
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)102,178101,31497,504

GH Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 141,647$ 492,202
Short-term marketable debt securities869,584440,546
Accounts receivable, net97,25697,652
Inventory, net51,59830,674
Prepaid expenses and other current assets, net31,50953,052
Total current assets1,191,5941,114,126
Long-term marketable debt securities0698,034
Property and equipment, net167,920124,461
Right-of-use assets, net174,001189,443
Intangible assets, net11,72714,207
Goodwill3,2903,290
Other assets, net61,45360,938
Total Assets[1]1,609,9852,204,499
Current liabilities:  
Accounts payable and accrued liabilities175,817105,361
Noncontrolling interest liability078,000
Deferred revenue17,40311,326
Total current liabilities193,220194,687
Convertible senior notes, net1,137,3911,134,821
Long-term operating lease liabilities210,015226,053
Other long-term liabilities9,1793,933
Total Liabilities[1]1,549,8051,559,494
Commitments and contingencies (Note 10)
Stockholders’ equity:  
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2022 and 202100
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, 2022 and 2021; 102,619,383 and 101,767,446 shares issued and outstanding as of December 31, 2022 and 2021, respectively11
Additional paid-in capital1,742,1141,657,593
Accumulated other comprehensive loss(19,522)(4,764)
Accumulated deficit(1,662,413)(1,007,825)
Total Stockholders’ Equity60,180645,005
Total Liabilities and Stockholders’ Equity$ 1,609,985$ 2,204,499
[1]As of December 31, 2021, the Company's consolidated balance sheet included $20.4 million of assets, that can be used only to settle obligations of Guardant Health AMEA, Inc., the consolidated variable interest entity, or VIE, and VIE’s subsidiaries, and $4.3 million of liabilities of the consolidated VIE and VIE’s subsidiaries, for which their creditors do not have recourse to the general credit of the Company. Guardant Health AMEA, Inc. is no longer a VIE, after the completion of the Joint Venture Acquisition on June 10, 2022. See Note 3, Joint Venture.